AVBP

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.

Wall Street analysts forecast AVBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVBP is 41.00 USD with a low forecast of 31.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ArriVent BioPharma Inc revenue for the last quarter amounts to -38.32M USD, increased 58.12 % YoY.

ArriVent BioPharma Inc. EPS for the last quarter amounts to -35798000.00 USD, decreased % YoY.

ArriVent BioPharma Inc (AVBP) has 52 emplpoyees as of December 15 2025.

Today AVBP has the market capitalization of 1.01B USD.